+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Phase 2
All Ages
All Genders
ID06975618

Study of Oral CYH33 to Assess Safety and Effects in Adults and Adolescents with PIK3CA-Related Overgrowth and Vascular Malformations

Led by Haihe Biopharma Co., Ltd. · Updated on 2026-06-29

141

Participants Needed

15

Research Sites

N/A

Total Duration

AI-Summary

What This Trial Is About

The trial investigates the safety, tolerability, pharmacokinetics, and preliminary effectiveness of CYH33, an oral selective PI3Kb1 inhibitor, in patients with PIK3CA-related overgrowth spectrum PROS and PIK3CA-related vascular malformations PRVM. This phase III, multi-center, open-label study aims to better understand how CYH33 works in these conditions, which involve abnormal tissue growth due to PIK3CA mutations. The study includes both adult and adolescent patients with confirmed diagnoses. The study consists of several cohorts phase I adult and adolescent cohorts receive escalating doses of CYH33 to find the maximum tolerated dose and recommended phase II dose. Phase II includes a PROS cohort receiving CYH33 at the recommended dose with possible dose escalation, continuing treatment until progression or toxicity. The PRVM cohort is randomized 21 to CYH33 or placebo for 8 weeks in a double-blind period, followed by an open-label extension where all receive CYH33. CYH33 is administered orally once daily, with starting doses varying by age group. Participants undergo regular assessments including pharmacokinetic sampling, safety monitoring, imaging to measure lesions, and patient-reported outcomes such as pain and quality of life. The study measures include objective response rates at various time points and drug concentration levels. Treatment continues until disease progression, unacceptable toxicity, or withdrawal, with follow-up lasting up to approximately 48 months. The sponsor is Haihe Biopharma Co., Ltd.

CONDITIONS

Brief Title

Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Preliminary Efficacy of CYH33 in Patients With PIK3CA-related Overgrowth Spectrum (PROS) and PIK3CA-related Vascular Malformations (PRVM)

Research Team

X

Xiaoxi Lin, MD

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here